Salmon calcitonin and the animal-vs-recombinant teaching case — how a fish hormone became an osteoporosis therapy
Calcitonin regulates calcium homeostasis in humans and inhibits osteoclasts. But human calcitonin acts clinically insufficiently. The pharmacological solution came from an unusual source: salmon calcitonin, which is 40-fold more potent in humans than the body's own. A story about the rare constellation in which a non-conspecific hormone is clinically superior to the body-identical one — and about the slow disappearance of a once widely prescribed therapy.
The discovery — and a surprise from salmon
Douglas Copp identified in Vancouver in 1962 a hormone of the thyroid C-cells that lowered serum calcium concentration — the mirror function of parathyroid hormone. He called it calcitonin. Human calcitonin is a 32-amino-acid peptide with an N-terminal disulphide ring and an amidated C-terminus, formed in the parafollicular C-cells of the thyroid.
In the following years calcitonins from various species were isolated and sequenced. A surprising observation: salmon calcitonin (Oncorhynchus keta) is identical to human calcitonin in only 14 of 32 amino acid positions — and about 40-fold more potent than human calcitonin in human bone resorption assays. The explanation lies in higher receptor affinity and longer plasma half-life (43 minutes for salmon calcitonin vs. under 10 minutes for human). A non-conspecific sequence is pharmacologically superior in this rare constellation.
From salmon to the clinic
Synthetic salmon calcitonin — produced by solid-phase peptide synthesis from the 1970s — was approved from the 1980s in several indications: Paget's disease (a rare bone disease), hypercalcaemia and postmenopausal osteoporosis. Original administration was intramuscular or subcutaneous; from 1995 an intranasal formulation (Miacalcin Nasal Spray) was available, substantially easing ambulatory use.
Through the 1990s and 2000s salmon calcitonin was a widely used osteoporosis therapy. It reduced vertebral fracture risk, had a friendly side-effect profile and was, compared with the bisphosphonates available at the time (alendronate from 1995, risedronate from 2000), often the preferred choice for patients with gastrointestinal tolerability issues. The analgesic effect in acute osteoporotic vertebral fractures — an interesting mechanistically not fully explained effect — additionally made it clinically attractive.
The decline from 2012
In 2012 the EMA published a combined analysis of multiple long-term salmon calcitonin trials showing an increased rate of malignancies — particularly prostate cancers — with long-term use. The absolute increase was small (about 0.7-2.4% additional risk) but consistent across multiple trials. The EMA recommended limiting use to the shortest possible therapy periods and withdrawing the intranasal formulation for the osteoporosis indication. The FDA followed with similar recommendations.
These safety signals, combined with the rise of modern osteoporosis therapies (denosumab — a monoclonal RANK ligand antibody — from 2010, teriparatide — a recombinant parathyroid hormone fragment — from 2002, romosozumab — a sclerostin antibody — from 2019), have practically displaced salmon calcitonin from modern therapy algorithms. It is still approved in most Western countries but rarely prescribed.
„It is a pharmacological curiosity: a hormone from a Pacific fish is more effective in humans than what the human thyroid itself produces. We understand the reason (sequence differences at the receptor), but we use it clinically less and less."
What the salmon calcitonin story methodologically shows
Three structural observations are valuable. First: the assumption that a body-identical peptide is pharmacologically optimal is not always correct. In rare constellations a non-conspecific analog can be superior — through higher receptor affinity, longer half-life or less receptor down-regulation on chronic use. Selection of the substance source is a pharmacological decision, not a biological default.
Second: long-term safety data can change an established therapy even after decades of use. Salmon calcitonin was a standard tool of osteoporosis therapy for 20+ years; a retrospective meta-analysis identified a previously unremarkable malignancy signal. This possibility of later re-evaluation is a property of every substance class often underestimated in popular discussion. Third: the appearance of better alternatives (denosumab, teriparatide, romosozumab) has changed the clinical position of salmon calcitonin without the substance itself worsening. Pharmacological 'significance' is relative to the available therapy landscape, not absolute.
Open questions
- Which other non-conspecific peptides could — through specific receptor constellations — be clinically superior to their human counterparts?
- Is the salmon calcitonin malignancy signal biologically grounded (chronic C-cell-line stimulation?) or an artefactual data-pooling problem?
- What role does salmon calcitonin still play in Paget's disease — a condition in which modern alternatives are less unambiguously superior?
- How does the osteoporosis therapy landscape change with the rise of anti-sclerostin antibodies (romosozumab) and new oral options?